Drug patent disputes impede US access to cheaper biosimilars
By Steve Scherer ( September 16, 2026, 23:31 GMT | Comment) -- An AAM report says costly US patent litigation is expected to leave 90 percent of the 118 biologics losing patent protection over the next decade without biosimilar competition. It could cost the healthcare system $189 billion in savings and prolong high prices for patients and taxpayers as consumers rank healthcare affordability among their top concerns.The United States could miss out on $189 billion in potential healthcare savings over the next decade because most biologic medicines approaching loss of exclusivity have no biosimilar competitor in development, according to an industry report that casts US patent litigation as an early and costly barrier to lower-priced competition....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.